The content on this site is intended for healthcare professionals only
The role of genomic testing in personalised medicine for breast cancer
Emerging strategies for the treatment of ovarian cancer
The evolving role of immunotherapy in oncology
Impact of imaging on radiotherapy
Challenges of imaging, radiation oncology, and a multidisciplinary organisation
Advancements in radiation oncology and medical physics
New epigenetic targets and the role of DNA methylation fingerprints in cancer treatment
Sarcoma UK: providing patient support and funding sarcoma research
2011 St Gallen Consensus breast cancer recommendations
Smaller, faster clinical trials
Opportunities for young oncologists attending EMCC 2011
Key benefits of the European Multidisciplinary Cancer Congress
Multidisciplinary cancer care and importance of patient involvement
A new light activated technique for delivery of anti-cancer drugs
Mechanisms of DNA damage processing in stem cells
Latest in renal carcinoma
Effect of economic, technological and social changes on global cancer burden
President of ECCO on EMCC 2011
Advances in the prevention of cervical cancer
Role of advance practice nurses in survivor care
Vemurafenib improves survival in melanoma with BRAF V600E mutation
Elimination of ageism from oncology
Angiogenesis therapy for colon cancer
Immunotherapy treatment for melanoma
Patterns of cancer incidence and mortality in Europe
Use of circulating tumour cells as a prognostic or predictive marker
Advances in the treatment of rectal cancer
EurocanPlatform - building a platform for translational research
Key gastrointestinal cancer research from EMCC 2011
Synchronous chemoradiation significantly reduces the risk of the breast cancer recurrence
Effects of radiotherapy on the immune system
Recent advances in advanced breast cancer
Advances in the treatment of lung cancer and melanoma
Multi-disciplinary approaches and e-learning within ESTRO
Message from the President of ESTRO
Message from the President-Elect of ESTRO
Benefits of the EMCC congress for young oncologists
The FLIMS Alumni Club
Influence of regenerative stem cells and cell microenvironment upon treatment success
Looking forward to the 2012 ESTRO meeting
Cancer risk communication
Mutations of the SF3B1 gene
60 years in oncology
Aflibercept vs placebo and FOLFIRI for MCRC
Roundup of the EMCC 2011 conference
Affordable cancer care in high-income countries
Effects of chemotherpay during pregnancy
Links between high blood pressure and cancer
The BOLERO-2 study confirms everolimus and exemestane in ER/PR+ advanced breast cancer improves PFS
Trastuzumab emtansine, Phase II trial for HER2
Radiotherapy between or during chemo cycles for breast cancer
Denosumab delays metastases for prostate cancer
Experimenting with smaller, faster clinical trials
Frequency of biopsies for breast cancer tumours
Zoledronic acid reduces recurrence of breast cancer
Cost effective ways to predict prostate cancer 1/2
Cost effective ways to predict prostate cancer 2/2
Phase III trial of an alpha-pharmaceutical
Chemotherapy infusions directly to organs
Personalising medicine and the panel’s predictions for oncotechnologies (2/4)
Advancing multidisciplinary cancer management (1/4)
Role, relevance and participation of all stakeholders in oncology (3/4)
Concluding remarks (4/4)
Bench, bedside, ‘bytes’ and back: a virtuous cycle of knowledge (1/5)
Personalised medicine: how the 2011 Multidisciplinary Cancer Congress will mark important milestones in getting the right treatment to the right patient at the right time (2/5)
Serendipity of cancer science & programme highlights (3/5)
Oncopolicy: tackling the inequalities in cancer research and care across Europe (4/5)
Multidisciplinary mass gathering and celebration of European basic, translational and clinical studies (5/5)
Battling rare cancers in Europe - access and ethics
Ethical considerations surrounding cancer in the elderly and the pros and cons of web-based resources
Access to new tailored cancer therapies and reliable patient information - the challenges
